Findings

What do systematic reviews say?

165 questions · 172 findings · 79 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 39 · 22.7%GRADE not reported 8 · 4.7%Very low 51 · 29.7%Low 51 · 29.7%Moderate 14 · 8.1%High 9 · 5.2%

Flumazenil vs placebo

All‐cause mortality · people with hepatic encephalopathy

Flumazenil showed no clear difference in all‐cause mortality compared with placebo (low certainty).

1 finding from 1 review

Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy 2017 · Cochrane Headline outcomes only
RR 0.75 [0.48, 1.16]
11 studies · 842 participants
Low

Intervention not reported

All‐cause mortality · children (aged 6 to 11 years) being overweight or obese

The review found no eligible studies for this question.

1 finding from 1 review

Diet, physical activity and behavioural interventions for the treatment of overweight or obese children from the age… 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

All‐cause mortality · adolescents (aged 12‐17 years) being overweight or obese

The review found no eligible studies for this question.

1 finding from 1 review

Diet, physical activity and behavioural interventions for the treatment of overweight or obese adolescents aged 12 to… 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Carvedilol vs placebo

All‐cause mortality · heart failure in patients with Chagas cardiomyopathy

It is very uncertain whether carvedilol changes all‐cause mortality compared with placebo (very low certainty).

1 finding from 1 review

Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy 2016 · Cochrane Headline outcomes only
RR 0.69 [0.12, 3.88]
2 studies · 69 participants
Very low

Rosuvastatin vs placebo

All‐cause mortality · chronic heart failure in Chagas cardiomyopathy patients

1 finding from 1 review

Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39 participants
GRADE not reported

Intervention not reported

All‐cause mortality · adults with type 2 diabetes and severe mental illness

The review found no eligible studies for this question.

1 finding from 1 review

Self management interventions for type 2 diabetes in adult people with severe mental illness 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

All‐cause mortality · preschool children (aged 0 to 6 years) with overweight or obesity

The review found no eligible studies for this question.

1 finding from 1 review

Diet, physical activity, and behavioural interventions for the treatment of overweight or obesity in preschool… 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

All‐cause mortality · preschool children (aged 0 to 6 years) with overweight or obesity

The review found no eligible studies for this question.

1 finding from 1 review

Diet, physical activity, and behavioural interventions for the treatment of overweight or obesity in preschool… 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

All‐cause mortality · obese children and adolescents

1 finding from 1 review

Drug interventions for the treatment of obesity in children and adolescents 2016 · Cochrane Headline outcomes only
no estimate extracted
20 studies · 2176 participants
Moderate

Amiodarone vs other antiarrhythmics

All‐cause mortality · participants with high risk of sudden cardiac death (secondary prevention)

Amiodarone showed no clear difference in all‐cause mortality compared with other antiarrhythmics (low certainty).

1 finding from 1 review

Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death 2015 · Cochrane Headline outcomes only
RR 1.03 [0.75, 1.42]
5 studies · 898 participants
Low

Amiodarone vs beta‐blocker

All‐cause mortality · participants with high risk of sudden cardiac death (secondary prevention)

It is very uncertain whether amiodarone changes all‐cause mortality compared with beta blockers (very low certainty).

1 finding from 1 review

Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death 2015 · Cochrane Headline outcomes only
RR 0.96 [0.7, 1.32]
1 study · 189 participants
Very low

Amiodarone vs sotalol

All‐cause mortality · participants with high risk of sudden cardiac death (secondary prevention)

It is very uncertain whether amiodarone changes all‐cause mortality compared with sotalol (very low certainty).

1 finding from 1 review

Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death 2015 · Cochrane Headline outcomes only
RR 1.08 [0.41, 2.83]
2 studies · 104 participants
Very low

Amiodarone vs placebo or no treatment

All‐cause mortality · participants with high risk of sudden cardiac death (primary prevention)

Amiodarone showed no clear difference in all‐cause mortality compared with placebo or no treatment (low certainty).

1 finding from 1 review

Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death 2015 · Cochrane Headline outcomes only
RR 0.88 [0.78, 1]
17 studies · 8383 participants
Low

Amiodarone vs beta‐blocker

All‐cause mortality · beta blockers

Amiodarone may leads to lower all‐cause mortality compared with beta blockers (low certainty).

1 finding from 1 review

Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death 2015 · Cochrane Headline outcomes only
RR 0.27 [0.1, 0.75]
2 studies · 342 participants
Low

Amiodarone vs other antiarrhythmics

All‐cause mortality · participants with high risk of sudden cardiac death (primary prevention)

Amiodarone probably leads to lower all‐cause mortality compared with other antiarrhythmics (moderate certainty).

1 finding from 1 review

Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death 2015 · Cochrane Headline outcomes only
RR 0.37 [0.18, 0.76]
3 studies · 540 participants
Moderate

Amiodarone vs placebo or no treatment

All‐cause mortality · participants with high risk of sudden cardiac death (secondary prevention)

It is very uncertain whether amiodarone changes all‐cause mortality compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death 2015 · Cochrane Headline outcomes only
RR 3.05 [1.33, 7.01]
2 studies · 440 participants
Very low

Low molecular weight heparin vs no prophylaxis

All‐cause mortality ( · adults undergoing KA

1 finding from 1 review

Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy 2022 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1978 participants
GRADE not reported

Remote monitoring plus usual care vs usual care

Mortality (all‐cause) · patients with chronic obstructive pulmonary disease

It is very uncertain whether remote monitoring plus usual care changes mortality (all‐cause) compared with usual care (very low certainty).

1 finding from 1 review

Telehealth interventions: remote monitoring and consultations for people with chronic obstructive pulmonary disease… 2021 · Cochrane Headline outcomes only
OR 0.99 [0.62, 1.58]
7 studies · 927 participants
Very low

Remote monitoring vs usual care

Mortality (all‐cause) · patients with chronic obstructive pulmonary disease

It is very uncertain whether remote monitoring changes mortality (all‐cause) compared with usual care (very low certainty).

1 finding from 1 review

Telehealth interventions: remote monitoring and consultations for people with chronic obstructive pulmonary disease… 2021 · Cochrane Headline outcomes only
OR 0.68 [0.37, 1.25]
6 studies · 798 participants
Very low

Intervention not reported

All‐cause mortality [ · participants with CHD after PCI

It is very uncertain whether the intervention changes all‐cause mortality [ (very low certainty).

1 finding from 1 review

Tong‐xin‐luo capsule for patients with coronary heart disease after percutaneous coronary intervention 2015 · Cochrane Headline outcomes only
RR 0.38 [0.06, 2.56]
4 studies · 419 participants
Very low